Navigation Links
Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
Date:6/8/2009

-543-6403 (U.S.) or 617-213-8896 (international), passcode: 12594792.

A replay of the call will be available from 1:00 pm Eastern Time on June 8, 2009 (7:00 pm Central European Time) through June 15, 2009. The replay number is 888-286-8010 (U.S.) or 617-801-6888 (international), passcode: 67386852.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal antibodies. BiTE antibodies represent a new class of antibodies that activate the T cells of a patient's immune system to eliminate cancer cells. Four of Micromet's antibodies are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma (NHL). A second BiTE antibody, MT110, is in a phase 1 clinical trial for the treatment of patients with solid tumors. MT110 binds to the epithelial cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to EpCAM and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after complete resection of liver metastases, and a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet's monoclonal antibody MT293, also known as TRC093, is licensed to TRACON Pharmaceuticals, Inc., and is in a phase 1 clinical trial for the treatment of patients with cancer.

In addition, Micromet has establishe
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
2. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
3. Clinical Data Published in Science Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab
4. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
5. Micromet Presents Update on Blinatumomabs Response Rate and Duration in a Phase 1 Study in Non-Hodgkins Lymphoma Patients
6. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
7. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
8. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
9. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
10. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
11. Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... -- STAAR Surgical Company (NASDAQ: STAA ), a leading developer, ... the eye today reported financial results for the second quarter ... , Net Sales of $18.7 Million Down 7% from ... $2.1 Million from the Weakening Euro and Yen , ... , APAC Sales Down 1% Including Korea - Up ...
(Date:7/29/2015)... 29, 2015  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... the second quarter ended June 30, 2015. ... HETLIOZ and Fanapt" said Mihael H. Polymeropoulos M.D., Vanda,s ... life cycle management of our products set the stage ... Financial Highlights , Total net product ...
(Date:7/29/2015)... NEWARK, Calif. , July 29, 2015 /PRNewswire/ ... "Company") today announced that its Board of Directors, ... its independent financial and legal advisors, has unanimously ... non-binding proposal from Horizon Pharma plc (NASDAQ: ... outstanding shares of Depomed in an all-stock transaction ...
Breaking Medicine Technology:STAAR Surgical Reports Second Quarter 2015 Results 2STAAR Surgical Reports Second Quarter 2015 Results 3STAAR Surgical Reports Second Quarter 2015 Results 4STAAR Surgical Reports Second Quarter 2015 Results 5STAAR Surgical Reports Second Quarter 2015 Results 6STAAR Surgical Reports Second Quarter 2015 Results 7STAAR Surgical Reports Second Quarter 2015 Results 8STAAR Surgical Reports Second Quarter 2015 Results 9STAAR Surgical Reports Second Quarter 2015 Results 10STAAR Surgical Reports Second Quarter 2015 Results 11STAAR Surgical Reports Second Quarter 2015 Results 12STAAR Surgical Reports Second Quarter 2015 Results 13STAAR Surgical Reports Second Quarter 2015 Results 14STAAR Surgical Reports Second Quarter 2015 Results 15STAAR Surgical Reports Second Quarter 2015 Results 16STAAR Surgical Reports Second Quarter 2015 Results 17STAAR Surgical Reports Second Quarter 2015 Results 18STAAR Surgical Reports Second Quarter 2015 Results 19STAAR Surgical Reports Second Quarter 2015 Results 20STAAR Surgical Reports Second Quarter 2015 Results 21STAAR Surgical Reports Second Quarter 2015 Results 22STAAR Surgical Reports Second Quarter 2015 Results 23STAAR Surgical Reports Second Quarter 2015 Results 24Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 2Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 3Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 4Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 5Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 6Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 7Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 8Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 9Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 10Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 11Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 12Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 13
... PARK, Calif., March 22, 2011 Telome Health, Inc. ... property portfolio. THI will provide telomere length data from ... health monitoring. THI leverages the predictive ... protective caps at the ends of chromosomes, to assess ...
... MOUNT PROSPECT, Ill., March 22, 2011 The National Association ... the prescription monitoring programs (PMPs) of North Dakota , ... agreements to participate in the PMP Interconnect ™ system, ... United States to be linked, providing a more effective means ...
Cached Medicine Technology:Telome Health, Inc. Launches With Exclusive IP Portfolio 2Telome Health, Inc. Launches With Exclusive IP Portfolio 3Three States Sign on to Participate in NABP's Interconnected Prescription Monitoring System 2Three States Sign on to Participate in NABP's Interconnected Prescription Monitoring System 3
(Date:7/29/2015)... ... July 29, 2015 , ... Angelo’s FabriClean, an area ... service: water damage restoration of carpets and rugs. The company will now reverse the ... commercial clients. , An overflowing overhead tank, rain leaking through an accidently left ...
(Date:7/29/2015)... ... July 29, 2015 , ... More than ... service providers of children living with autism will converge upon Penn State to ... , The National Autism Conference will be held Aug. 3-6 at the ...
(Date:7/29/2015)... NY (PRWEB) , ... July 29, 2015 , ... ... Fitness as a sponsor, with its Topricin® Pain Relief and Healing Cream designated ... a firefighter-founded web-based organization that is actively addressing Line of Duty Deaths (LODD) ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... This year, ... record-setting precipitation levels this spring. And, where there is water, mold is not far ... property, offers tips for protecting against water and mold damage. Paul Davis is regularly ...
(Date:7/29/2015)... ... July 29, 2015 , ... CrossFit 269, offering a nationally ... Kalamazoo Strength & Conditioning. , The name change coincides with the release of ... training center over the past three years,” according to Jack Kelly, the center’s ...
Breaking Medicine News(10 mins):Health News:Angelo’s FabriClean Now Offers Water Damage Restoration For Residential and Commercial Accounts 2Health News:Penn State Conference to Address Instruction, Success for Children with Autism 2Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 2Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 3Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 4Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 5Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 6Health News:Paul Davis Offers Tips to Minimize Property Damage and Health Risks This Flood Season 2Health News:Paul Davis Offers Tips to Minimize Property Damage and Health Risks This Flood Season 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 2Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 4
... received a $1.6 million grant from the National Cancer ... by the body,s immune system, allowing cancer to develop ... Health grant will enable researchers led by Alex Y. ... biomedical engineering at the School of Medicine, and a ...
... , THURSDAY, March 31 (HealthDay News) -- There may ... a common congenital heart defect, a new study suggests. U.S. ... diagnosed with migraines and treated at the Primary Children,s Medical Center ... team checked each child,s heart for a patent foramen ovale (PFO) ...
... immune tolerance field continues to grow. Following the ... October 2009, the Second International Conference on Immune ... their latest research and insights into the mechanisms ... transplantation, autoimmune diseases, inflammation and cancer. This Conference ...
... WEST LAFAYETTE, Ind. - Eating fewer, regular-sized meals with higher ... than eating smaller, more frequent meals, according to new research ... amounts of protein, men who were trying to lose weight ... in late-night desire to eat and had fewer thoughts of ...
... is growing evidence that the risk factors for ... risk factors for developing addiction in adolescence are ... is associated with the highest addiction risk. Traits ... behavioral disinhibition, and devaluation of the future negative ...
... 31 (HealthDay News) -- An antibacterial agent that,s an ingredient ... in the bodies of fish, finds a new study. ... concerns due to its potential hormone-disrupting effects. Bioaccumulation occurs ... unable to metabolize and excrete the chemical quickly enough, allowing ...
Cached Medicine News:Health News:Case Western Reserve receives $1.6M to study tumor cells and immune cell detection 2Health News:2nd International Conference on Immune Tolerance 2Health News:STUDY: 3 square meals a day paired with lean protein help people feel full during weight loss 2Health News:STUDY: 3 square meals a day paired with lean protein help people feel full during weight loss 3Health News:STUDY: 3 square meals a day paired with lean protein help people feel full during weight loss 4Health News:Different genes influence smoking risk during adolescence and adulthood 2Health News:Antibacterial Soap Additive Accumulates in Fish: Study 2
Anti-Tg and Anti-TPO are two major autoantibodies implicated in autoimmune related thyroiditis and aid in the differential diagnosis of Hashimoto's thyroiditis and Graves' disease....
... is an automated, turbidimetric, whole- blood assay ... the ability of activated platelets to bind ... of the VerifyNow IIb/IIIa assay device contains ... this analysis. Within the well is an ...
... The Company's first commercial product is ... with single-use, disposable assay devices . The ... products are direct use of a vacuum-type ... a result in minutes. VerifyNow IIb/IIIa, the ...
... ComboMap system provides both pressure and ... singly or in a combined screen ... SmartWire and Volcano's unique Doppler FloWire. ... valuable tools to assess ambiguous or ...
Medicine Products: